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How	often	should	you	follow	up	
on	a	patient	with	newly		
diagnosed	hypothyroidism?
evidence-based answer
six to 8 weeks after the start of 
levothyroxine therapy you should reexamine 
patients and measure their serum thyroid-
stimulating hormone (TsH) (strength of 
recommendation [sor]: c, common 
practice and expert opinion). If thyroid 
function is normal at that time, examine 
the patient and measure serum TsH again 
in 4 to 6 months because clearance of 
levothyroxine increases in the euthyroid 
(normal) state (sor: c, expert opinion). 
 once the proper maintenance dose 
of levothyroxine is achieved, evaluate the 
patient and obtain a serum TsH at least 
annually, or as clinically indicated (sor: c, 
expert opinion).
z	Evidence	summary
There is very little patient-oriented re-
search to help answer this question. 
Virtually all of the literature is based on 
bench research and expert opinion. 
Wait	at	least	6	weeks		
to	follow	up	after	starting	therapy
Serial serum TSH measurements are 
adequate to follow adults with newly 
diagnosed, uncomplicated primary hypo-
thyroidism. However, serum thyroid hor-
mone levels normalize before serum TSH. 
Serum thyroid hormone concentrations 
increase first, then the TSH secretion falls 
because of the negative feedback action 
of levothyroxine on the pituitary and hy-
pothalamus. Levothyroxine has a 1-week 
plasma half-life; a steady state is achieved 
about 6 weeks (6 half-lives) after the start 
of treatment or a change in dose. The 
TSH level should, therefore, be evaluated 
no earlier than 6 weeks after initiating 
therapy or adjusting levothyroxine dos-
age.1,2 The full effects of thyroid hormone 
replacement on the TSH level may not be-
come apparent until 8 weeks of therapy.3 
Check	TSH	4	to	6	months		
after	initial	follow-up	
If the initial dose doesn’t require adjust-
ment, reevaluate the patient and measure 
serum TSH again in 4 to 6 months because 
levothyroxine clearance can increase after 
the euthyroid state is established.4 If a dos-
age change is needed, make adjustments 
every 6 weeks, based on serum TSH val-
ues, until TSH values return to the refer-
ence range. Successful treatment reverses 
all the signs and symptoms of hypothy-
roidism, although some neuropsychologic 
and biochemical abnormalities, such as 
depressed mood and lipid abnormalities, 
may persist for several months.3 
Monitor	stable	patients	annually,	
especially	the	elderly
Examine the patient and measure serum 
Patients older 
than 65 years 
must be monitored 
annually to avoid 
overreplacement
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TSH annually after identifying the prop-
er maintenance dose, more often if an ab-
normal result or a change in the patient’s 
status occurs.2 Certain situations such as 
pregnancy, initiation of new medications, 
or liver or kidney disease may require 
more frequent monitoring. 
Generally, once a stable maintenance 
dosage of levothyroxine is achieved, the 
dosage will remain adequate until the 
patient has a significant weight change 
or reaches his or her seventh or eighth 
decade.1 Although monitoring less often 
than once a year can be justified in young-
er adult patients whose weight is stable, 
patients older than 65 years must be mon-
itored annually to avoid overreplacement. 
With age, thyroid binding may decrease, 
and the serum albumin level may decline. 
This can result in a 20% reduction in the 
dose of levothyroxine required.5,6 
Recommendations
The American Association of Clinical 
Endocrinologists (AACE) recommends 
reassessment and repeat lab work at 
least 6 weeks after any change in levo-
thyroxine brand or dose. The AACE 
practice guidelines suggest follow-up 
with appropriate interim history, physi-
cal exam, and pertinent lab studies at 
6 months, and then annually after the 
TSH level has normalized.7 n
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Diabetes. Cancer. Obesity. Respiratory 
disease. America’s medical professionals 
are busier than ever. How can they stay 
current with medical advances and still 
improve their patients’ well-being? 
Information is part of quality care. Yet 
government controls threaten to keep 
doctors in the dark about current  
medical advances. 
Restrictions on how much information 
consumers and doctors can know about 
current and new treatments reduce  
their ability to advocate for care. 
Using censorship as a policy tool to  
control healthcare costs is a bad idea!  
Yet that’s what vocal pockets of academic 
medicine and Congress have in mind. 
We are concerned that some members 
of Congress and academia are seeking 
to restrict the content of CME and other 
industry-sponsored communications 
without input from practicing physicians. 
Information is the first step to care.  
To learn more, visit cohealthcom.org. 
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